Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-α

Blood

Volumn 93, Issue 9, 1999, Pages 2991-2998

  Kockx, Maaike ^b   Gervois, Philippe P ^b   Poulain, Philippe ^b   Derudas, Bruno ^b   Peters, Jeffrey M ^b   Gonzalez, Frank J ^b   Princen, Hans M G ^b   Kooistra, Teake ^a   Staels, Bart ^b  

^a TNO   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CIPROFIBRATE; COMPLEMENTARY DNA; FENOFIBRIC ACID; FIBRIC ACID DERIVATIVE; FIBRONECTIN; GEMFIBROZIL; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RNA; ROSIGLITAZONE;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; FIBRINOGEN BLOOD LEVEL; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033134791     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.9.2991     Document Type: Article

References (45)

1. Handley DA, Hughes TE: Pharmacological approaches and strategies for therapeutic modulation of fibrinogen. Thromb Res 87:1, 1997
2. Oliver MF: Fibrinogen and coronary heart disease - what does it mean? Eur Heart J 19:8, 1998
3. Ernst E, Resch KL: Therapeutic interventions to lower plasma fibrinogen concentration. Eur Heart J 16:47, 1995
4. Branchi A, Rovelline A, Sommariva D, Gugliandolo AG, Faoli A: Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen levels in patients with primary hypercholesterolemia. Thromb Haemost 70:241, 1993
5. Schonfeld G: The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis 111:161, 1994
6. Schoonjans K, Staels B, Auwerx J: Role of peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 27:907, 1996
7. Lemberger T, Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: A nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 12:335, 1996
8. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ: Targeted disruption of the a isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15:3012, 1995
9. Peters JM, Hennuyer N, Staels B, Fruchart J, Fievet C, Gonzalez FJ, Auwerx J: Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice. J Biol Chem 272: 27307, 1997
10. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ: Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem 273:5678, 1998
11. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart J, Najib J, Maclouf J, Tedgui A: Activation of human aortic smooth-mucle cells is inhibited by PPARα but not by PPARγ activators. Nature 393:790, 1998
12. Staels B, VanTol A, Andreu T, Auwerx J: Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Aterioscler Thromb 12:286, 1992
13. Princen HMG, Huijsmans CMG, Kuipers F, Vonk RJ, Kempen HJM: Ketoconazole blocks bile acid synthesis in hepatocyte monolayer cultures and in vivo in rat by inhibiting cholesterol 7α-hydroxylase. J Clin Invest 78:1064, 1986
14. Koopman J, Maas A, Rezaee F, Havekes J, Verheijen J, Gijbels M, Haverkate F: Fibrinogen and atherosclerosis: A study in transgenic mice. Fibrinol Proteol 11:19, 1997
15. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156, 1987
16. Arts J, Kockx M, Princen HMG, Kooistra T: Studies on the mechanism of fibrate-inhibited expression of plasminogen activator inhibitor-1 in cultured hepatocytes from cynomolgus monkey. Arterioscler Thromb Vasc Biol 17:26, 1997
17. Miyazawa S, Osumi T, Hashimoto T, Ohno K, Miura S, Fujiki Y: Peroxisome targeting signal of rat liver acyl-coenzyme A oxidase resides at the carboxy terminus. Mol Cell Biol 9:83, 1989
18. Wilson GN, Hollar BA, Waterson JR, Schmickel RD: Molecular analysis of cloned human 18S ribosomal DNA segments. Proc Natl Acad Sci USA 75:5367, 1978
19. Gorski K, Carneiro M, Schibler U: Tissue-specific in vitro transcription from the mouse albumin promoter. Cell 47:767, 1986
20. Nevins JR: Isolation and analysis of nuclear RNA. Methods Enzymol 152:234, 1987
21. Hirose S, Oda K, Ikehara Y: Biosynthesis, assembly and secretion of fibrinogen in cultured rat hepatocytes. Biochem J 251:373, 1988
22. Forman BM, Chen J, Evans RM: Hypolipidemic drugs, polyun-saturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci USA 94:4312, 1997
23. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma). J Biol Chem 270:12953, 1995
24. Fuller GM: Fibrinogen: A multifunctional acute phase protein, in Mackiewicz A, Kushner I, Baumann H (eds): Acute Phase Proteins: Molecular Biology, Biochemistry, and Clinical Applications, New York, NY, Doubleday, 1993, p 169
25. Kant JA, Fornace AJ, Saxe D, Simon MI, McBride OW, Crabtree GR: Evolution and organization of the fibrinogen locus on chromosome 4: Gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci USA 82:2344, 1985
26. Yu S, Sher B, Kudryk B, Redman CM: Intracellular assembly of human fibrinogen. J Biol Chem 258:13407, 1983
27. Roy SN, Mukhopadhyay G, Redman CM: Regulation of fibrinogen assembly. Transfection of Hep G2 cells with B beta cDNA specifically enhances synthesis of the three component chains of fibrinogen. J Biol Chem 265:6389, 1990
28. Binsack R, Stegmeier K, Dörge L, Völkl A: Bezafibrate down-regulates fibrinogen biosynthesis in human hepatoma HepG2 cells. Eur J Clin Invest 28:151, 1998
29. Vu-Dac N, Schoonjans K, Laine B, Fruchart J, Auwerx J, Staels B: Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferater-activated receptor with its response element. J Biol Chem 269:31012, 1994
30. Schoonjans K, Peinado-Onsurbe J, Lefebvre A, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J: PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15:5336, 1996
31. Schoonjans K, Watanabe M, Suzuki H, Mahfoudi A, Krey G, Wahli W, Grimaldi P, Staels B, Yamamoto T, Auwerx J: Induction of the acyl-coenzyme A synthase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem 270:19269, 1995
32. Baumann H: Hepatic acute phase reaction in vivo and in vitro. In Vitro Cell Dev Biol 25:115, 1989
33. Castell JV, Gomez-Lechon MJ, David M, Andus T, Geiger R, Trullenque R, Fabra R, Heinrich PC: Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 242:237, 1989
34. Hu CH, Harris JE, Davie EW, Chung DW: Characterization of the 5′-flanking region of the gene for the alpha chain of human fibrinogen. J Biol Chem 270:28342, 1995
35. Dalmon J, Laurent M, Courtois G: The human β fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6-responsive element. Mol Cell Biol 13:1183, 1993
36. Fowlkes DM, Mullis NT, Comeau CM, Crabtree GR: Potential basis for regulation of the coordinately expressed fibrinogen genes: Homology in the 5′ flanking regions. Proc Natl Acad Sci USA 81:2313, 1984
37. Spiegelman BM: PPARγ in monocytes: Less pain, any gain? Cell 93:153, 1998
38. 4 pathway to inflammation control. Nature 384:39, 1996
39. Markowe HL, Marmot MG, Shipley MJ, Bulpitt CJ, Meade TW, Stirling Y, Vickers MV, Semmence A: Fibrinogen: A possible link between social class and coronary heart disease. BMJ 291:1312, 1985
40. Stout RW, Crawford VL: Seasonal variations in fibrinogen concentrations among elderly people. Lancet 338:9, 1991
41. Mayer J, Eller T, Brauer P, Solleder EM, Schafer RM, Keller F, Kochsiek K: Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 64:196, 1992
42. Tugwood JD, Aldridge TC, Lambe KG, Macdonald N, Woodyatt NJ: Peroxisome proliferator-activated receptors: Structures and function. Ann N Y Acad Sci 804:252, 1996
43. Beigel Y, Fuchs J, Snir M, Green P, Lune Y, Djaldetti M: Lovastatin therapy in hypercholesterolemia: Effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol 31:512, 1991
44. Jay RH, Rampling MW, Betteridge DJ: Abnormalities of blood rheology in familial hypercholesterolaemia: Effects of treatment. Artherosclerosis 85:249, 1990
45. Bisgaier CL, Essenburg AD, Barnett BC, Auerbach BJ, Haubenwallner S, Leff T, White D, Creger P, Pape ME, Rea T, Newton RS: A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. J Lipid Res 39:17, 1998